After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Earlier, Yahoo Finance discussed this stock as it revealed ARWR: Pipeline Reprioritization to Reduce Cash Burn by up to $100 Million This Fiscal Year.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Arrowhead Pharmaceuticals Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Arrowhead Pharmaceuticals Inc. is $3.74B. A total of 1.21 million shares were traded on the day, compared to an average of 1.61M shares.
Insider Activity
Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, ARWR has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 3 BUYs and 13 SELLs from insiders. Insiders purchased 162,683 shares during that period but sold 234,221.
In the most recent transaction, Anzalone Christopher Richard sold 57,499 shares of ARWR for 32.35 per share on Jan 31. After the transaction, the Chief Executive Officer now owns 3,715,048 company shares. In a previous transaction on Jan 12, Hamilton James C sold 7,940 shares at 36.89 per share. ARWR shares that Chief Discovery/Trans Medicine owns now total 210,851.
Among the insiders who sold shares, Vakiener Victoria disposed of 4,720 shares on Jan 11 at a per-share price of $38.10. This resulted in the Director holding 32,001 shares of ARWR after the transaction. In another insider transaction, Waddill William D. sold 3,934 shares at $38.07 per share on Jan 11. Company shares held by the Director now total 47,870.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for ARWR in the last 3 months, the mean price target is $55.15 with high estimates of $90.00 and low estimates of $28.00. In terms of 52-week highs and lows, ARWR has a high of $42.48 and a low of $20.67.
As of this writing, ARWR has an earnings estimate of -$0.16 per share for the current quarter. EPS was calculated based on a consensus of 12 estimates, with a high estimate of $3.27 per share and a lower estimate of -$0.95. The company reported an EPS of -$1.02 in the last quarter, which was -70.00% lower than expectations of -$0.6.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. ARWR’s latest balance sheet shows that the firm has $367.79M in Cash & Short Term Investments as of fiscal 2021. There were $25.55M in debt and $146.54M in liabilities at the time. Its Book Value Per Share was $1.49, while its Total Shareholder’s Equity was $408.82M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ARWR is Buy with a score of 4.31.
